n(1)-methylnicotinamide has been researched along with Alloxan Diabetes in 5 studies
N(1)-methylnicotinamide: RN given refers to parent cpd
1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Comparisons were made of the dose-response and time-course characteristics of nicotinamide (NIC) and its metabolite, N1-methylnicotinamide (MNIC), protection from alloxan-induced diabetes in mice." | 5.27 | Characteristics of nicotinamide and N1-methylnicotinamide protection from alloxan diabetes in mice. ( Falany, J; Fischer, LJ; Fisher, R, 1983) |
| "Comparisons were made of the dose-response and time-course characteristics of nicotinamide (NIC) and its metabolite, N1-methylnicotinamide (MNIC), protection from alloxan-induced diabetes in mice." | 1.27 | Characteristics of nicotinamide and N1-methylnicotinamide protection from alloxan diabetes in mice. ( Falany, J; Fischer, LJ; Fisher, R, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 1 |
| Zhang, J | 1 |
| Li, P | 1 |
| Liu, C | 1 |
| Li, L | 1 |
| Przyborowski, K | 1 |
| Wojewoda, M | 1 |
| Sitek, B | 1 |
| Zakrzewska, A | 1 |
| Kij, A | 1 |
| Wandzel, K | 1 |
| Zoladz, JA | 1 |
| Chlopicki, S | 2 |
| Kuchmerovska, T | 1 |
| Shymanskyy, I | 1 |
| Klimenko, A | 1 |
| Országhová, Z | 1 |
| Uličná, O | 1 |
| Liptáková, A | 1 |
| Zitňanová, I | 1 |
| Muchová, J | 1 |
| Watala, C | 1 |
| Duračková, Z | 1 |
| Fischer, LJ | 1 |
| Falany, J | 1 |
| Fisher, R | 1 |
5 other studies available for n(1)-methylnicotinamide and Alloxan Diabetes
| Article | Year |
|---|---|
N1‑methylnicotinamide ameliorates insulin resistance in skeletal muscle of type 2 diabetic mice by activating the SIRT1/PGC‑1α signaling pathway.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin Receptor Sub | 2021 |
Effects of 1-Methylnicotinamide (MNA) on Exercise Capacity and Endothelial Response in Diabetic Mice.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Epoprostenol; | 2015 |
1-methylnicotinamide (MNA) in prevention of diabetes-associated brain disorders.
Topics: Animals; Brain Diseases; Diabetes Mellitus, Experimental; Male; Niacinamide; Rats; Serotonin; Signal | 2010 |
Effects of N1-methylnicotinamide on oxidative and glycooxidative stress markers in rats with streptozotocin-induced diabetes mellitus.
Topics: Animals; Antioxidants; Biomarkers; Diabetes Mellitus, Experimental; DNA Damage; Drug Evaluation, Pre | 2012 |
Characteristics of nicotinamide and N1-methylnicotinamide protection from alloxan diabetes in mice.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; | 1983 |